Literature DB >> 11323215

Recent advances in melanoma research.

T Saida1.   

Abstract

Recent advancement in the research of malignant melanoma is reviewed. Among many gene alterations detected in human melanoma, defect of CDKN2A located at chromosome 9p21 seems to be most important in the earlier developmental phase, though significance of this gene in the evolution of melanoma in situ has not been confirmed yet. Deletions of PTEN/MMAC1 on 10q23.3 and AIM1 on 6q21 as well as mutations of ras gene are involved in the later progression stages of melanoma. Adhesion molecules relevant to development and progression of melanoma have been intensely investigated in recent years, revealing crucial roles of cadherins and alpha(v)beta(3) integrin in the biologic behaviors of melanoma cells. Melanoma is characterized by extremely high potential of developing metastases. Dynamic changes of matrix metalloproteinase activity during invasion and movement of melanoma cells may be a major concern in this field. Fragility of blood vessels in melanoma lesions is another important point related to hematogeneous metastases. Acral lentiginous melanoma is a unique subtype of melanoma, because, in contrast to other subtypes, ultraviolet irradiation is not a major factor in its development. Investigation of pathogenesis of acral lentiginous melanoma surely provides us with new information about mechanism of melanocyte transformation. Recent advances in the management of malignant melanoma are also briefly reviewed, such as biochemotherapy, immunotherapy, and gene therapy. Finally, the concept of molecular classification of melanoma by gene expression profile is introduced, which possibly enables us to give the tailor-made therapy for each melanoma patient in the near future.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323215     DOI: 10.1016/s0923-1811(01)00085-8

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  7 in total

1.  [Diagnosis of melanocytic tumours : Old and new problems with an increasingly common tumour group].

Authors:  T Mentzel
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

2.  Using RNA sequencing for identifying gene imprinting and random monoallelic expression in human placenta.

Authors:  Tauno Metsalu; Triin Viltrop; Airi Tiirats; Balaji Rajashekar; Ene Reimann; Sulev Kõks; Kristiina Rull; Lili Milani; Ganesh Acharya; Purusotam Basnet; Jaak Vilo; Reedik Mägi; Andres Metspalu; Maire Peters; Kadri Haller-Kikkatalo; Andres Salumets
Journal:  Epigenetics       Date:  2014-10       Impact factor: 4.528

3.  Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Rian Disci; Sidika Kurul; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 4.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

5.  Aberrant V(D)J recombination is not required for rapid development of H2ax/p53-deficient thymic lymphomas with clonal translocations.

Authors:  Craig H Bassing; Sheila Ranganath; Mike Murphy; Velibor Savic; Meagan Gleason; Frederick W Alt
Journal:  Blood       Date:  2007-09-13       Impact factor: 22.113

6.  Therapeutic Implications of Targeting AKT Signaling in Melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Enzyme Res       Date:  2011-03-23

7.  Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.

Authors:  N Soufir; J J Lacapere; G Bertrand; E Matichard; R Meziani; D Mirebeau; V Descamps; B Gérard; A Archimbaud; L Ollivaud; F Bouscarat; M Baccard; G Lanternier; P Saïag; C Lebbé; N Basset-Seguin; B Crickx; H Cave; B Grandchamp
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.